918523-57-6

Basic information

• Product Name: N-(2,4-difluorophenyl)propane-1-sulfonaMide
• Synonyms: N-(2,4-difluorophenyl)propane-1-sulfonaMide
• CAS NO: 918523-57-6
• Molecular Formula: C₉H₁₁F₂NO₂S
• Molecular Weight: 235
• Mol File: 918523-57-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2,4-difluorophenyl)propane-1-sulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-difluorophenyl)propane-1-sulfonaMide(918523-57-6)
• EPA Substance Registry System: N-(2,4-difluorophenyl)propane-1-sulfonaMide(918523-57-6)

Safety Data

• Hazardous Substances Data: 918523-57-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2,4-difluorophenyl)propane-1-sulfonamide is used as an antibacterial and antimicrobial agent for the treatment of various bacterial infections. It functions by inhibiting the synthesis of dihydrofolic acid in bacteria, which in turn prevents the production of essential nucleic acids, thereby effectively combating bacterial growth.
Used in Antibiotic Development:
N-(2,4-difluorophenyl)propane-1-sulfonamide plays a significant role in the development of new antibiotics. Its unique properties contribute to the creation of novel compounds with enhanced antibacterial capabilities, addressing the growing challenge of antibiotic resistance.
Used in Treatment of Infectious Diseases:
N-(2,4-difluorophenyl)propane-1-sulfonamide is employed in the treatment of a wide range of infectious diseases caused by bacteria. Its effectiveness in inhibiting bacterial growth makes it a crucial component in the management and control of various infections, improving patient outcomes and overall public health.

Upstream product

• 10147-36-1 n-propanesulfonyl chloride 
• 367-25-9 2,4-difluorophenylamine 

Downstream Products

• 1254566-59-0 5-{3-[2,6-difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridine-2-carboxylic acid ethylamide 
• 1254566-58-9 5-(3-{[2,6-difluoro-3-(propane-1-sulfonylamino)-phenyl]-hydroxy-methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridine-2-carboxylic acid ethylamide 
• 918505-84-7 N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonoamide 
• 1021854-28-3 N-(3-((5-chloro-1H-pyrrolo[2,3-b]pyridine-3-yl)(hydroxyl)methyl)2,4-difluorophenyl)propane-1-sulfonamide 
• 1029872-54-5 vemurafenib 
• 918523-58-7 N-(2,4-difluoro-3-formylphenyl)propane-1-sulfonamide 

Relevant articles and documents

Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research

We report dramatically improved total syntheses of two highly selective V600EBRAF inhibitors, PLX4720 and PLX4032, that leverages microwave-assisted organic synthesis (MAOS). Compared with previously reported approaches, our novel MAOS method significantly reduces overall reaction time without compromising yield. In addition to providing a gram-scale route to these compounds for preclinical oncology research, we anticipate this approach could accelerate the synthesis of azaindoles in high-throughput, library-based formats.

PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES

Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide, pyrrolidine-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, N,N-dimethylamino-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, glioma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, and biliary tract cancer.

PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE

Compounds (I) and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf -1 protein kinase, and may also be active on either or both of A-Raf and B-Raf V600E protein kinase. Also described are methods of use thereof to treat diseases and conditions, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, and biliary tract cancer.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R2 is hydrogen, lower alkyl or halogen; U is selected from the group consisting of -S(O)2-, -C(X)-, -C(X)-N(R10)-, and -S(O)2-N(R10)-; R3 is optionally substituted lower alkyl, optionally substituted C3.6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and wherein R1, R3, R4, m, L1, X R10 are as described herein.

PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Compounds of formula III which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.